This is the 1st Quarter 2009 edition of our ongoing hedge fund portfolio tracking series. Before reading this update, make sure you check out the Hedge Fund 13F filings series preface.
Next up is Shumway Capital Partners run by Chris Shumway. Shumway started his own fund after leaving well-known Julian Robertson's Tiger Management. Thus, as a progeny of Robertson, he is a part of what people call the 'Tiger Cubs' (people who have started their own firms after succeeding at Tiger). Shumway became Robertson's right-hand man after former #2 John Griffin left to start Blue Ridge Capital. We've already covered many of the 'Tiger Cub' funds in our series including Stephen Mandel's Lone Pine Capital, Andreas Halvorsen's Viking Global, and Lee Ainslie's Maverick Capital.
Taken from our post on 'Tiger Cub' biographies, "Chris Shumway is the Founding Partner of Shumway Capital Partners (“SCP”), an investment management firm founded in 2001. SCP, which manages a multibillion dollar group of private investment funds, uses a private equity-like research model for public market investment on a global basis. Prior to forming SCP, Mr. Shumway was a Senior Managing Director at Tiger Management (1992-1999), an Analyst at Brentwood Associates (1990-1991), and an Analyst at Morgan Stanley & Co. (1988-1990). He received an M.B.A. from Harvard Business School (1993) and a B.S. from the McIntire School of Commerce at the University of Virginia (1988)." In the past at a 'Tiger Cub' hedge fund manager panel, Shumway suggested that buying stocks that were down largely due to hedge fund liquidations would be a winning strategy longer-term. Lastly, in terms of more recent activity, Shumway has filed a 13G on Equinix (EQIX).
Recently, Shumway Capital Partners was ranked #11 in Barron's top 100 hedge fund rankings for 2009; an impressive feat. Barron's list is ranked according to a rolling 3 year annualized return and Shumway has seen a 28.7% annualized performance by this metric.
Shumway's solid performance and stock picking has landed them in our custom Market Folly portfolio, created with Alphaclone. Our portfolio (which has Shumway's stock picks in it, amongst others) is up 14.4% year-to-date for 2009 and has seen 19.8% annualized returns since mid-2002. The numbers are quite impressive and it speaks to the success Shumway has had since striking out on his own. With that in mind, let's check out their portfolio.
The following were Shumway's long equity, note, and options holdings as of March 31st, 2009 as filed with the SEC. We have not detailed the changes to every single position in this update, but we have covered all the major moves. All holdings are common stock unless otherwise denoted.
Some New Positions (Brand new positions that they initiated in the last quarter):
Wyeth (WYE), Microsoft (MSFT), Pfizer (PFE), Walmart (WMT), Walgreens (WAG), Zimmer Holdings (ZMH), Disney (DIS), Costco (COST), Ishares Emerging Markets (EEM), RenaissanceRe (RNR), Arch Capital (ACGL), JPMorgan Chase (JPM), Hudson City Bancorp (HCBK), International Game Technology (IGT), Partnerre (PRE), & Citigroup (C).
Some Increased Positions (A few positions they already owned but added shares to)
Cisco Systems (CSCO): Increased by 15,982% (their position quarter prior was tiny)
EMC (EMC): Increased by 8,821%
Potash (POT): Increased by 968%
SBA Communications (SBAC): Increased by 633%
Teva Pharma (TEVA): Increased by 615%
CVS Caremarkt (CVS): Increased by 533%
Qualcomm (QCOM): Increased by 189%
Equinix (EQIX): Increased by 103%
Union Pacific (UNP): Increased by 91%
Savvis (SVVS) Bonds: Increased by 67%
Mastercard (MA): Increased by 50%
American Tower (AMT): Increased by 43%
St Jude Medical (STJ): Increased by 38%
Some Reduced Positions (Some positions they sold some shares of - note not all sales listed)
Qualcomm (QCOM) Calls: Reduced by 41%
Removed Positions (Positions they sold out of completely)
Biogen Idec (BIIB), Waters (WAT), News Corp (NWS-A), Thermo Fisher Scientific (TMO), Stryker (SYK), Hansen Natural (HANS), Celanese (CE), Cogent (CCOI) Calls, & NII Holdings (NIHD).
Top 15 Holdings (by % of portfolio)
- Teva Pharma (TEVA): 10.2% of portfolio
- Wyeth (WYE): 7.6% of portfolio
- Cisco Systems (CSCO): 7.1% of portfolio
- Mastercard (MA): 7% of portfolio
- St Jude Medical (STJ): 6.15% of portfolio
- CVS Caremark (CVS): 5.3% of portfolio
- Microsoft (MSFT): 4.11% of portfolio
- EMC (EMC): 4% of portfolio
- Visa (V): 3.77% of portfolio
- Equinix (EQIX): 3.76% of portfolio
- American Tower (AMT): 3.7% of portfolio
- Pfizer (PFE): 3.65% of portfolio
- Walmart (WMT): 3.64% of portfolio
- Walgreens (WAG): 3.6% of portfolio
- Qualcomm (QCOM) Calls: 3.5% of portfolio
The biggest story here is their massive additions to their Teva Pharma (TEVA) and Cisco Systems (CSCO) positions. They increased their TEVA stake by over 600% and brought it up to their largest holding. Their CSCO stake is now their 3rd largest after boosting their position by almost 16,000%. Like Maverick Capital who we just looked at last week, Shumway has also started a nice sized position in Walgreens (WAG). Maverick has much more conviction in the name though, as they brought it up to their top holding, while Shumway holds it at their #14 slot.
Additionally, we see yet another hedge fund that has entered the Wyeth (WYE) trade to the long side in an effort to game the merger arbitrage/event-driven strategy. Two positions worth noting that they sold completely out of are Biogen Idec (BIIB) and Waters (WAT). Previously, those positions had been 9.6% and 6.7% positions for Shumway, which was pretty substantial. But, they no longer own those names as Shumway's portfolio turnover is somewhat more frequent than other typical fundamental funds we follow. Lastly, we want to highlight that Shumway is obviously bullish on both Mastercard (MA) and Visa (V), along with numerous other hedge funds. In particular, we've noticed a lot of the 'Tiger Cub' funds holding shares of these payment processors.
Assets from the collective holdings reported to the SEC via 13F filing were $3.1 billion this quarter compared to $1 billion last quarter, as they put a substantial amount of capital to work on the long side of their portfolio, tripling their exposure. As you can tell from the 'increased positions category, they were definitely out adding across the board to portfolio names they already owned. And, they started brand new large positions in Wyeth (WYE) and Microsoft (MSFT) as well.
Their purchases will have proved to be very timely as the market has rallied substantially. It will be interesting to see if/when they decide to reduce some long exposure after so heavily beefing it up this past quarter. This is just one of the 40+ prominent funds that we'll be covering in our hedge fund Q1 2009 portfolio series. Check back each day as we cover new fund portfolios. We've already covered Andreas Halvorsen's Viking Global, John Paulson's hedge fund Paulson & Co, Stephen Mandel's Lone Pine Capital, Eric Mindich's Eton Park Capital, John Griffin's Blue Ridge Capital, and David Einhorn's Greenlight Capital, Seth Klarman's Baupost Group, Timothy Barakett's Atticus Capital, Lee Ainslie's Maverick Capital, and Raj Rajaratnam's Galleon Group.